Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Impact of induction therapy on bacterial infections and long-term outcome in adult intestinal and multivisceral transplantation: a comparison of two different induction protocols: daclizumab vs. alemtuzumab.

Kimura T, Lauro A, Cescon M, Zanfi C, Dazzi A, Ercolani G, Grazi GL, Vivarelli M, Ravaioli M, Del Gaudio M, Cucchetti A, Zanello M, LaBarba G, Pironi L, Lazzarotto T, Pinna AD.

Clin Transplant. 2009 Jun-Jul;23(3):420-5.

PMID:
19537304
2.

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.

Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, Zanello M, Vivarelli M, Del Gaudio M, Ravaioli M, Cucchetti A, Vetrone G, Tuci F, Di Gioia P, Lazzarotto T, D'Errico A, Bagni A, Faenza S, Siniscalchi A, Pironi L, Pinna AD.

Transplant Proc. 2010 Jan-Feb;42(1):35-8. doi: 10.1016/j.transproceed.2009.12.019.

PMID:
20172276
3.

Evolutionary experience with immunosuppression in pediatric intestinal transplantation.

Bond GJ, Mazariegos GV, Sindhi R, Abu-Elmagd KM, Reyes J.

J Pediatr Surg. 2005 Jan;40(1):274-9; discussion 279-80.

PMID:
15868597
4.

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.

Lauro A, Amaduzzi A, Dazzi A, Ercolani G, Zanfi C, Golfieri L, Grazi GL, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Siniscalchi A, Faenza S, D'Errico A, Di Simone M, Pironi L, Pinna AD.

Dig Liver Dis. 2007 Mar;39(3):253-6. Epub 2007 Feb 1.

PMID:
17275428
5.

Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation.

Tzakis AG, Kato T, Nishida S, Levi DM, Tryphonopoulos P, Madariaga JR, De Faria W, Nery JR, Regev A, Vianna R, Miller J, Esquenazi V, Weppler D, Ruiz P.

Transplantation. 2003 May 15;75(9):1512-7.

PMID:
12792506
6.

Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.

Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim SH, Kim HJ, Cho SG, Eom KS, Lee JW, Min WS, Shin WS, Kim CC.

Transpl Infect Dis. 2009 Oct;11(5):413-23. doi: 10.1111/j.1399-3062.2009.00414.x. Epub 2009 Aug 24.

PMID:
19708893
7.

Kidney after nonrenal transplantation-the impact of alemtuzumab induction.

Shapiro R, Basu A, Tan HP, Morgan C, Sharma V, Blisard D, Randhawa PS, Dvorchik I, McCauley J, Ellis D, Marsh JW, Webber S, Kurland G, McCurry KR, Abu-Elmagd K, Mazariegos G, Starzl TE.

Transplantation. 2009 Sep 27;88(6):799-802. doi: 10.1097/TP.0b013e3181b4aaf5.

8.

Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.

Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, Shutt KA, Shapiro R, Thai N, Abu-Elmagd K, McCurry KR, Marcos A, Paterson DL.

Clin Infect Dis. 2007 Jan 15;44(2):204-12. Epub 2006 Dec 13.

PMID:
17173218
9.
10.
11.

Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.

Yuan-Xin L, Ning L, You-Sheng L, Xiao-Dong N, Ming L, Jian W, Jie-Shou L.

Transplant Proc. 2010 Jan-Feb;42(1):29-34. doi: 10.1016/j.transproceed.2009.12.028.

PMID:
20172275
12.

Campath-1H induction and the incidence of infectious complications in adult renal transplantation.

Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S.

Transplantation. 2006 Jan 15;81(1):17-20.

PMID:
16421471
13.

Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients.

Nishida S, Levi DM, Moon JI, Madariaga JR, Kato T, Selvaggi G, Tryphonopoulos P, DeFaria W, Santiago S, Gaynor J, Weppler D, Martinez E, Ruiz P, Tzakis AG.

Transplant Proc. 2006 Jul-Aug;38(6):1747-9.

PMID:
16908270
14.

Results of intestinal and multivisceral transplantation in adult patients: Italian experience.

Lauro A, Dazzi A, Ercolani G, Cescon M, D'Errico A, Di Simone M, Grazi GL, Vivarelli M, Varotti G, De Ruvo N, Masetti M, Cautero N, Di Benedetto F, Siniscalchi A, Begliomini B, Lazzarotto T, Faenza S, Pironi L, Pinna AD.

Transplant Proc. 2006 Jul-Aug;38(6):1696-8.

PMID:
16908252
16.

Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.

Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.

Liver Transpl. 2005 Jan;11(1):61-7.

17.

Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.

Schadde E, D'Alessandro AM, Knechtle SJ, Odorico J, Becker Y, Pirsch J, Sollinger H, Fernandez LA.

Transpl Int. 2008 Jul;21(7):625-36. doi: 10.1111/j.1432-2277.2008.00642.x. Epub 2008 Apr 4.

18.

Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin.

Lischke R, Simonek J, Davidová R, Schützner J, Stolz AJ, Vojácek J, Burkert J, Pafko P.

Transplant Proc. 2007 Jan-Feb;39(1):205-12.

PMID:
17275507
19.

Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?

Cheung CY, Liu YL, Wong KM, Chan HW, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Shek CC, Li CS.

Nephrology (Carlton). 2008 Jun;13(3):251-5. doi: 10.1111/j.1440-1797.2007.00911.x. Epub 2008 Jan 23.

PMID:
18221256
20.

Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab.

Brock MV, Borja MC, Ferber L, Orens JB, Anzcek RA, Krishnan J, Yang SC, Conte JV.

J Heart Lung Transplant. 2001 Dec;20(12):1282-90.

PMID:
11744411

Supplemental Content

Support Center